Stockscreener 앱 받기
1.66
2.35%
-0.04
시간 외 거래:
1.74
0.08
+4.82%
전일 마감가:
$1.70
열려 있는:
$1.7
하루 거래량:
244.92K
Relative Volume:
0.92
시가총액:
$85.27M
수익:
-
순이익/손실:
$-13.27M
주가수익비율:
-10.12
EPS:
-0.164
순현금흐름:
$-7.70M
1주 성능:
-2.35%
1개월 성능:
-15.31%
6개월 성능:
-26.22%
1년 성능:
+31.75%
1일 변동 폭
$1.60
$1.72
1주일 범위
$1.60
$1.79
52주 변동 폭
$1.03
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.66 | 87.33M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-08 | 개시 | B. Riley Securities | Buy |
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
OKYO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026 - Proactive financial news
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026 - TipRanks
OKYO Pharma's Urcosimod Selected for Presentation at ARVO 2026 Annual Meeting Following Positive Phase 2a Trial Results for Neuropathic Corneal Pain Treatment - Quiver Quantitative
OKYO (Nasdaq: OKYO) to present Fast Track NCP therapy data at ARVO 2026 - Stock Titan
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress - GlobeNewswire
Analysts Set OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Target Price at $6.00 - Defense World
Piper Sandler Initiates Coverage on OKYO Pharma (NASDAQ:OKYO) - Defense World
OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler - MarketBeat
Piper Sandler initiates OKYO Pharma stock with Overweight rating By Investing.com - Investing.com Nigeria
How OKYO Pharma Limited stock compares to industry benchmarksWeekly Trade Review & Daily Volume Surge Signals - mfd.ru
CEO Moves: Is OKYO Pharma Limited a turnaround story2025 Pullback Review & Weekly High Return Stock Forecasts - baoquankhu1.vn
How interest rate cuts could boost OKYO Pharma Limited stockJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - mfd.ru
Piper Sandler initiates OKYO Pharma stock with Overweight rating - Investing.com South Africa
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Piper Sandler Initiates Coverage on OKYO Pharma With Overweight Rating, $7 Price Target - marketscreener.com
Big Money Moves: How interest rate cuts could boost OKYO Pharma Limited stock2025 Investor Takeaways & Entry and Exit Point Strategies - mfd.ru
OKYO Pharma prices public offering at $1.85/share to raise up to $20M - MSN
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares - VisionMonday.com
Small cap wrap: Trust Stamp, HIVE Digital Technologies, OKYO Pharma... - Proactive financial news
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain - Proactive financial news
What risks investors should watch in OKYO Pharma Limited stock2025 Market Sentiment & Technical Entry and Exit Alerts - mfd.ru
Options Flow: Is OKYO Pharma Limited exposed to political riskQuarterly Investment Review & Safe Capital Allocation Plans - baoquankhu1.vn
Income Plays: Is Amylyx Pharmaceuticals Inc in accumulation or distribution phaseJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Support Test: Is APWC a strong candidate for buy and holdJuly 2025 Review & Expert Curated Trade Setups - baoquankhu1.vn
Can OKYO Pharma Limited stock deliver sustainable ROEPortfolio Performance Report & Growth Focused Stock Reports - mfd.ru
OKYO Pharma Prices Public Offering at $1.85 per Share - Intellectia AI
OKYO PE Ratio & Valuation, Is OKYO Overvalued - Intellectia AI
Is OKYO Pharma Limited a turnaround storyWeekly Stock Analysis & Reliable Price Breakout Signals - mfd.ru
Small cap wrap: OKYO Pharma, HIVE Digital Technologies, Synchronoss Technologies... - Proactive financial news
Published on: 2026-02-14 12:01:38 - baoquankhu1.vn
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Sees Significant Increase in Short Interest - MarketBeat
OKYO Pharma launches underwritten public offering of ordinary shares - MSN
OKYO Pharma announces $20 million public offering of ordinary shares - Investing.com South Africa
OKYO Pharma announces $20 million public offering of ordinary shares By Investing.com - Investing.com Canada
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development - TipRanks
OKYO Pharma stock tumbles on $20 million public offering announcement - Investing.com South Africa
OKYO Pharma stock tumbles on $20 million public offering announcement By Investing.com - Investing.com Canada
OKYO Pharma prices $20M offering to fund late-stage eye drug trial - Yahoo Finance
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline - TipRanks
What’s the analyst consensus on OKYO Pharma LimitedOptions Play & Technical Entry and Exit Tips - mfd.ru
Okyo Pharma Limited (OKYO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):